The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I:

##STR00001##

wherein W, X, Y, Z, R.sup.1, R.sup.2, R.sup.5, and R.sup.8 are as described herein.

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I:

##STR00001##

wherein W, X, Y, Z, R.sup.1, R.sup.2, R.sup.5, and R.sup.8 are as described herein.

Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).